|
1
|
Novara G, Martignoni G, Artibani W and
Ficarra V: Grading systems in renal cell carcinoma. J Urol.
177:430–436. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Massari F, Bria E, Maines F, Milella M,
Giannarelli D, Cognetti F, Pappagallo G, Tortora G and Porta C:
Adjuvant treatment for resected renal cell carcinoma: Are all
strategies equally negative? Potential implications for trial
design with targeted agents. Clin Genitourin Cancer. 11:471–476.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keizman D, Rouvinov K, Sella A, Gottfried
M, Maimon N, Kim JJ, Eisenberger MA, Sinibaldi V, Peer A, Carducci
MA, et al: Is there a ‘Trial Effect’ on outcome of patients with
metastatic renal cell carcinoma treated with sunitinib? Cancer Res
Treat. 48:281–287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van der Mijn JC, Mier JW, Broxterman HJ
and Verheul HM: Predictive biomarkers in renal cell cancer:
Insights in drug resistance mechanisms. Drug Resist Updat.
17:77–88. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao B, Lei QY and Guan KL: The Hippo-YAP
pathway: New connections between regulation of organ size and
cancer. Curr Opin Cell Biol. 20:638–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao B, Li L, Lei Q and Guan KL: The
Hippo-YAP pathway in organ size control and tumorigenesis: An
updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu H, Jiang D, Chi F and Zhao B: The
Hippo pathway regulates stem cell proliferation, self-renewal, and
differentiation. Protein Cell. 3:291–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao B, Tumaneng K and Guan KL: The Hippo
pathway in organ size control, tissue regeneration and stem cell
self-renewal. Nat Cell Biol. 13:877–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Halder G and Johnson RL: Hippo signaling:
Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moya IM and Halder G: The Hippo pathway in
cellular reprogramming and regeneration of different organs. Curr
Opin Cell Biol. 43:62–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wierzbicki PM and Rybarczyk A: The Hippo
pathway in colorectal cancer. Folia Histochem Cytobiol. 53:105–119.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Janse van Rensburg HJ and Yang X: The
roles of the Hippo pathway in cancer metastasis. Cell Signal.
28:1761–1772. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Johnson R and Halder G: The two faces of
Hippo: Targeting the Hippo pathway for regenerative medicine and
cancer treatment. Nat Rev Drug Discov. 13:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai J, Zhang N, Zheng Y, De Wilde RF,
Maitra A and Pan D: The Hippo signaling pathway restricts the
oncogenic potential of an intestinal regeneration program. Genes
Dev. 24:2383–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morinaga N, Shitara Y, Yanagita Y, Koida
T, Kimura M, Asao T, Kimijima I, Takenoshita S, Hirota T, Saya H,
et al: Molecular analysis of the h-warts/LATS1 gene in human breast
cancer. Int J Oncol. 17:1125–1129. 2000.PubMed/NCBI
|
|
17
|
Wierzbicki PM, Adrych K, Kartanowicz D,
Stanislawowski M, Kowalczyk A, Godlewski J, Skwierz-Bogdanska I,
Celinski K, Gach T, Kulig J, et al: Underexpression of LATS1 TSG in
colorectal cancer is associated with promoter hypermethylation.
World J Gastroenterol. 19:4363–4373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin XY, Zhang XP, Wu JH, Qiu XS and Wang
EH: Expression of LATS1 contributes to good prognosis and can
negatively regulate YAP oncoprotein in non-small-cell lung cancer.
Tumour Biol. 35:6435–6443. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou D, Conrad C, Xia F, Park JS, Payer B,
Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, et al: Mst1 and
Mst2 maintain hepatocyte quiescence and suppress hepatocellular
carcinoma development through inactivation of the Yap1 oncogene.
Cancer Cell. 16:425–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miyanaga A, Masuda M, Tsuta K, Kawasaki K,
Nakamura Y, Sakuma T, Asamura H, Gemma A and Yamada T: Hippo
pathway gene mutations in malignant mesothelioma: Revealed by RNA
and targeted exon sequencing. J Thorac Oncol. 10:844–851. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bora-Singhal N, Nguyen J, Schaal C,
Perumal D, Singh S, Coppola D and Chellappan S: YAP1 regulates OCT4
activity and SOX2 expression to facilitate self-renewal and
vascular mimicry of stem-like cells. Stem Cells. 33:1705–1718.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Machado-Neto JA, Lazarini M, Favaro P,
Franchi GC Jr, Nowill AE, Saad ST and Traina F: ANKHD1, a novel
component of the Hippo signaling pathway, promotes YAP1 activation
and cell cycle progression in prostate cancer cells. Exp Cell Res.
324:137–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vlug EJ, van de Ven RA, Vermeulen JF, Bult
P, van Diest PJ and Derksen PW: Nuclear localization of the
transcriptional coactivator YAP is associated with invasive lobular
breast cancer. Cell Oncol (Dordr). 36:375–384. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li M, Lu J, Zhang F, Li H, Zhang B, Wu X,
Tan Z, Zhang L, Gao G, Mu J, et al: Yes-associated protein 1 (YAP1)
promotes human gallbladder tumor growth via activation of the
AXL/MAPK pathway. Cancer Lett. 355:201–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu YC and Wang YZ: Role of Yes-associated
protein 1 in gliomas: Pathologic and therapeutic aspects. Tumour
Biol. 36:2223–2227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Klacz J, Wierzbicki PM, Wronska A,
Rybarczyk A, Stanislawowski M, Slebioda T, Olejniczak A,
Matuszewski M and Kmiec Z: Decreased expression of RASSF1A tumor
suppressor gene is associated with worse prognosis in clear cell
renal cell carcinoma. Int J Oncol. 48:55–66. 2016.PubMed/NCBI
|
|
27
|
Wierzbicki PM, Klacz J, Rybarczyk A,
Slebioda T, Stanislawowski M, Wronska A, Kowalczyk A, Matuszewski M
and Kmiec Z: Identification of a suitable qPCR reference gene in
metastatic clear cell renal cell carcinoma. Tumour Biol.
35:12473–12487. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wojdacz TK and Dobrovic A:
Methylation-sensitive high resolution melting (MS-HRM): A new
approach for sensitive and high-throughput assessment of
methylation. Nucleic Acids Res. 35:e412007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Avădănei ER, Wierzbicki PM, Giuşcă SE,
Grigoraş A, Amălinei C and Căruntu ID: Macrophage profile in
primary versus secondary liver tumors. Folia Histochem Cytobiol.
52:112–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union against Cancer: TNM classification of
malignant tumours. Wiley-Blackwell; Chichester, West Sussex, UK;
Hoboken, NJ: 2010
|
|
32
|
Delahunt B, Sika-Paotonu D, Bethwaite PB,
Jordan T William, Magi-Galluzzi C, Zhou M, Samaratunga H and
Srigley JR: Grading of clear cell renal cell carcinoma should be
based on nucleolar prominence. Am J Surg Pathol. 35:1134–1139.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin L, Sabnis AJ, Chan E, Olivas V, Cade
L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, et al: The Hippo
effector YAP promotes resistance to RAF- and MEK-targeted cancer
therapies. Nat Genet. 47:250–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang L, Yang S, Chen X, Stauffer S, Yu F,
Lele SM, Fu K, Datta K, Palermo N, Chen Y, et al: The hippo pathway
effector YAP regulates motility, invasion, and castration-resistant
growth of prostate cancer cells. Mol Cell Biol. 35:1350–1362. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mei L, Yuan L, Shi W, Fan S, Tang C, Fan
X, Yang W, Qian Y, Hussain M and Wu X: SUMOylation of large tumor
suppressor 1 at Lys751 attenuates its kinase activity and
tumor-suppressor functions. Cancer Lett. 386:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saucedo LJ and Edgar BA: Filling out the
Hippo pathway. Nat Rev Mol Cell Biol. 8:613–621. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu FX, Zhao B and Guan KL: Hippo pathway
in organ size control, tissue homeostasis, and cancer. Cell.
163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nokin MJ, Durieux F, Peixoto P, Chiavarina
B, Peulen O, Blomme A, Turtoi A, Costanza B, Smargiasso N, Baiwir
D, et al: Methylglyoxal, a glycolysis side-product, induces Hsp90
glycation and YAP-mediated tumor growth and metastasis. eLife.
5:52016. View Article : Google Scholar
|
|
39
|
Chen KH, He J, Wang DL, Cao JJ, Li MC,
Zhao XM, Sheng X, Li WB and Liu WJ: Methylation associated
inactivation of LATS1 and its effect on demethylation or
overexpression on YAP and cell biological function in human renal
cell carcinoma. Int J Oncol. 45:2511–2521. 2014.PubMed/NCBI
|
|
40
|
Zhang H, Geng D, Gao J, Qi Y, Shi Y, Wang
Y, Jiang Y, Zhang Y, Fu J, Dong Y, et al: Expression and
significance of Hippo/YAP signaling in glioma progression. Tumour
Biol. 37:15665–15676. 2016. View Article : Google Scholar
|
|
41
|
He J, Tang F, Liu L, Chen L, Li J, Ou D,
Zhang L, Li Z, Feng D, Li W, et al: Positive regulation of TAZ
expression by EBV-LMP1 contributes to cell proliferation and
epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Oncotarget. Dec 2–2016.(Epub ahead of print).
doi.org/10.18632/oncotarget.13775. View Article : Google Scholar
|
|
42
|
Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G
and Lu D: Promoter hypermethylation-mediated down-regulation of
LATS1 and LATS2 in human astrocytoma. Neurosci Res. 56:450–458.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sasaki H, Hikosaka Y, Kawano O, Yano M and
Fujii Y: Hypermethylation of the large tumor suppressor genes in
Japanese lung cancer. Oncol Lett. 1:303–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Oh JE, Ohta T, Satomi K, Foll M, Durand G,
McKay J, Le Calvez-Kelm F, Mittelbronn M, Brokinkel B, Paulus W, et
al: Alterations in the NF2/LATS1/LATS2/YAP pathway in schwannomas.
J Neuropathol Exp Neurol. 74:952–959. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Reddy VR, Annamalai T, Narayanan V and
Ramanathan A: Hypermethylation of promoter region of LATS1 - a CDK
interacting protein in oral squamous cell carcinomas - a pilot
study in India. Asian Pac J Cancer Prev. 16:1599–1603. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Karamitopoulou E, Zlobec I, Patsouris E,
Peros G and Lugli A: Loss of E-cadherin independently predicts the
lymph node status in colorectal cancer. Pathology. 43:133–137.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li L, Fang R, Liu B, Shi H, Wang Y, Zhang
W, Zhang X and Ye L: Deacetylation of tumor-suppressor MST1 in
Hippo pathway induces its degradation through HBXIP-elevated HDAC6
in promotion of breast cancer growth. Oncogene. 35:4048–4057. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rawat SJ and Chernoff J: Regulation of
mammalian Ste20 (Mst) kinases. Trends Biochem Sci. 40:149–156.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liang K, Zhou G, Zhang Q, Li J and Zhang
C: Expression of hippo pathway in colorectal cancer. Saudi J
Gastroenterol. 20:188–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Seidel C, Schagdarsurengin U, Blümke K,
Würl P, Pfeifer GP, Hauptmann S, Taubert H and Dammann R: Frequent
hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol
Carcinog. 46:865–871. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Piccolo S, Dupont S and Cordenonsi M: The
biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev.
94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Plouffe SW, Hong AW and Guan KL: Disease
implications of the Hippo/YAP pathway. Trends Mol Med. 21:212–222.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhou D, Zhang Y, Wu H, Barry E, Yin Y,
Lawrence E, Dawson D, Willis JE, Markowitz SD, Camargo FD, et al:
Mst1 and Mst2 protein kinases restrain intestinal stem cell
proliferation and colonic tumorigenesis by inhibition of
Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA.
108:E1312–E1320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cao JJ, Zhao XM, Wang DL, Chen KH, Sheng
X, Li WB, Li MC, Liu WJ and He J: YAP is overexpressed in clear
cell renal cell carcinoma and its knockdown reduces cell
proliferation and induces cell cycle arrest and apoptosis. Oncol
Rep. 32:1594–1600. 2014.PubMed/NCBI
|
|
55
|
Dong C, Wei KJ, Zhang WB, Sun H, Pan HY
and Zhang L: LATS2 induced by TNF-alpha and inhibited cell
proliferation and invasion by phosphorylating YAP in oral squamous
cell carcinoma. J Oral Pathol Med. 44:475–481. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
He C, Lv X, Hua G, Lele SM, Remmenga S,
Dong J, Davis JS and Wang C: YAP forms autocrine loops with the
ERBB pathway to regulate ovarian cancer initiation and progression.
Oncogene. 34:6040–6054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jerhammar F, Johansson AC, Ceder R,
Welander J, Jansson A, Grafström RC, Söderkvist P and Roberg K:
YAP1 is a potential biomarker for cetuximab resistance in head and
neck cancer. Oral Oncol. 50:832–839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Konsavage WM Jr, Kyler SL, Rennoll SA, Jin
G and Yochum GS: Wnt/β-catenin signaling regulates Yes-associated
protein (YAP) gene expression in colorectal carcinoma cells. J Biol
Chem. 287:11730–11739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yuan H, Liu H, Liu Z, Zhu D, Amos CI, Fang
S, Lee JE and Wei Q: Genetic variants in Hippo pathway genes
YAP1TEAD1TEAD4 are associated with melanoma-specific survival. Int
J Cancer. 137:638–645. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhao J, Li X, Yang Y, Zhu D, Zhang C, Liu
D, Wu K and Zhao S: Effect of YAP1 silencing on esophageal cancer.
Onco Targets Ther. 9:3137–3146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li P, Sun D, Li X, He Y, Li W, Zhao J,
Wang Y, Wang H and Xin Y: Elevated expression of Nodal and YAP1 is
associated with poor prognosis of gastric adenocarcinoma. J Cancer
Res Clin Oncol. 142:1765–1773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liao T, Wen D, Ma B, Hu JQ, Qu N, Shi RL,
Liu L, Guan Q, Li DS and Ji QH: Yes-associated protein 1 promotes
papillary thyroid cancer cell proliferation by activating the
ERK/MAPK signaling pathway. Oncotarget. Feb 14–2017.(Epub ahead of
print). doi.org/10.18632/oncotarget.14319.
|
|
63
|
Pan Y, Robertson G, Pedersen L, Lim E,
Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X,
et al: miR-509-3p is clinically significant and strongly attenuates
cellular migration and multi-cellular spheroids in ovarian cancer.
Oncotarget. 7:25930–25948. 2016.PubMed/NCBI
|
|
64
|
Xu R, Zeng G, Gao J, Ren Y, Zhang Z, Zhang
Q, Zhao J, Tao H and Li D: miR-138 suppresses the proliferation of
oral squamous cell carcinoma cells by targeting Yes-associated
protein 1. Oncol Rep. 34:2171–2178. 2015.PubMed/NCBI
|
|
65
|
Xiao L, Zhou H, Li XP, Chen J, Fang C, Mao
CX, Cui JJ, Zhang W, Zhou HH, Yin JY, et al: MicroRNA-138 acts as a
tumor suppressor in non small cell lung cancer via targeting YAP1.
Oncotarget. 7:40038–40046. 2016.PubMed/NCBI
|
|
66
|
Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS,
Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC, et al: Significant
association of oncogene YAP1 with poor prognosis and cetuximab
resistance in colorectal cancer patients. Clin Cancer Res.
21:357–364. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Song S, Honjo S, Jin J, Chang SS, Scott
AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et
al: The Hippo coactivator YAP1 mediates EGFR overexpression and
confers chemoresistance in esophageal cancer. Clin Cancer Res.
21:2580–2590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Touil Y, Igoudjil W, Corvaisier M, Dessein
AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G,
et al: Colon cancer cells escape 5FU chemotherapy-induced cell
death by entering stemness and quiescence associated with the
c-Yes/YAP axis. Clin Cancer Res. 20:837–846. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wang DY, Wu YN, Huang JQ, Wang W, Xu M,
Jia JP, Han G, Mao BB and Bi WZ: Hippo/YAP signaling pathway is
involved in osteosarcoma chemoresistance. Chin J Cancer. 35:472016.
View Article : Google Scholar : PubMed/NCBI
|
